Amneal Pharmaceuticals has signed an agreement with Kashiv BioSciences to license orphan drug K127 (pyridostigmine) to treat myasthenia gravis.
7 November 2019 News
29 October 2019 News
Gilead has announced it will be leveraging Glympse Bio’s synthetic biomarker technology to support its nonalcoholic steatohepatitis (NASH) clinical development programme.
23 October 2019 Analysis
Takeda has published promising real-world data for its UC and CD drug Entyvio, which suggest the drug is better tolerated by patients than four anti-TNFα therapies. Takeda’s Global Gastroenterology Outcomes...
22 October 2019 Comment
Vaccines for influenza and pertussis protect the mother and child from potentially high-risk complications.
15 October 2019 Comment
Ra Pharmaceuticals focuses on assets that selectively inhibit the complement system and other immune targets, including its lead pipeline drug Zilucoplan.
11 October 2019 News
UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn.
7 October 2019 Comment
Both GPA and MPA are associated with severe symptoms and can be life-threatening disorders, so the approval of Rituxan has filled a serious unmet need.
29 August 2019 News
AstraZeneca has announced anifrolumab met the primary endpoint of the Phase III Tulip trial studying 373 systemic lupus erythematosus (SLE) patients.